Guided Therapeutics (GTHP) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 6.31.
- Guided Therapeutics' Equity Ratio fell 6031.01% to 6.31 in Q3 2025 from the same period last year, while for Sep 2025 it was 6.31, marking a year-over-year decrease of 6031.01%. This contributed to the annual value of 3.55 for FY2024, which is 5558.16% down from last year.
- Per Guided Therapeutics' latest filing, its Equity Ratio stood at 6.31 for Q3 2025, which was down 6031.01% from 5.85 recorded in Q2 2025.
- Guided Therapeutics' Equity Ratio's 5-year high stood at 0.0 during Q1 2024, with a 5-year trough of 6.31 in Q3 2025.
- Over the past 5 years, Guided Therapeutics' median Equity Ratio value was 2.58 (recorded in 2021), while the average stood at 2.59.
- In the last 5 years, Guided Therapeutics' Equity Ratio crashed by 18395.01% in 2023 and then skyrocketed by 9972.8% in 2024.
- Guided Therapeutics' Equity Ratio (Quarter) stood at 2.67 in 2021, then soared by 67.91% to 0.86 in 2022, then plummeted by 166.25% to 2.28 in 2023, then plummeted by 55.58% to 3.55 in 2024, then tumbled by 77.92% to 6.31 in 2025.
- Its Equity Ratio was 6.31 in Q3 2025, compared to 5.85 in Q2 2025 and 0.01 in Q1 2025.